About the recently held congress of the Russian society of urologists says doctor of medical sciences.

"We're on a wide range of topical issues of modern urology, but the main of them are concerned, first of all, the treatment of diseases of the prostate gland prostate cancer and benign prostate hyperplasia (BPH).

As for prostate cancer, then at the present time for this disease is a special situation: in case of timely diagnosis of this malignant tumor she successfully amenable to effective treatment. But, unfortunately, the identification of the disease in the majority of cases is untimely, because many patients go to the doctor too late.

Other, no less important and relevant for today were issues relating to the diagnosis and treatment of benign hyperplasia of the prostate gland. The satellite symposium in the framework of the congress was presented with a new drug for the treatment of this disease - Avodart, which recently started to be used by specialists in our country - and with very good therapeutic effect.


In addition, the congress was elected the new melting of our Society. Chairman of the Society of urologists, as before, and again became an academician Nikolai Lopatkin, what I and many of our colleagues are accepted with great enthusiasm.

- Who can be useful information, presented in the reports of the congress?

- In my opinion, it is extremely important both for urologists, as well as for physicians of general practice. Benign hyperplasia of the prostate gland, about the treatment which was discussed at the congress, is a very common disease in the world, including in Russia. Thus, the frequency of occurrence of the disease in men aged 50 years is 50% (the disease occurs every second), among the 60-year-old patient she is diagnosed in 60% of cases, the 70-year-olds-in 70%. These patients are treated like to urologists, and to doctors of the general practice, therefore, for these physicians such knowledge are also very important. Use in medical work presented at the congress of the information can greatly enhance the effectiveness of the therapy of this disease, which is of great importance both for the health of the Russian men in general and of each of them in particular.

- Why do leading urologists and in our country, and all over the world more often express the opinion about the necessity of pathogenetic therapy BPH?

"The fact is that only pathogenetic therapy can relieve the patient of the disease, while symptomatic treatment is not free from it - it only reduces the symptoms of the disease. Let's say, a doctor comes to a patient with benign hyperplasia of the prostate gland , and he, not knowing about the existence of new, more effective medicines, appoints symptomatic treatment. In the course of therapy the patient feels a little better, but the tumor continues to grow! To the extent of the growth of the patient at first feels generally fine, but then, when the tumor reaches a large volume, his condition is much worse. But at this time it will be too late to appoint pathogenetic therapy, and have to resort already for the surgical treatment. But let us remember the fact that patients with hyperplasia of the prostate gland, which most of all - elderly people, and in most cases have a lot of related diseases, including diseases of the cardio-vascular system. Often these patients showed operative intervention, but we can't make such an operation, because otherwise the risk of considerably worsen the condition of the patient: in some cases, patients having heavy, poorly compensated diseases of the cardio-vascular system, there are absolute contraindications for surgery. Therefore, the presence in our arsenal of drugs type "Avodart" - it is a huge advantage in the struggle with BPH.

- That is, in those cases, when there is pathogenetic treatment of the disease, the need for surgical treatment of adenoma is no longer?

"Quite right - but if it pathogenetic treatment will be administered in a timely manner, that is, the patient time to turn to a specialist. Unfortunately, many of the men in our country is not enough closely related to their health and to go to the doctor only when, without his help was not needed. Fortunately, in recent times, in connection with the revival in our country the system of prophylactic medical examination, the state of affairs in this area is gradually improve.

- In the framework of the congress was held satellite symposium Glaxosmithkline. What questions on it discussed?

- The central theme of the symposium was to discuss the problems of timely diagnosis and treatment of patients with benign hyperplasia of the prostate gland. At this symposium, we had the opportunity to further discuss this very important issue and share experiences on the application of different treatment methods and opportunities of conservative treatment of this disease.

At the symposium, as I have already said, was also presented a new product for pathogenetic treatment of benign hyperplasia of the prostate gland - "Avodart". In spite of the fact that this is a relatively new drug, it is already actively used in the treatment of this disease doctors-urologists. The information presented at the symposium gives an opportunity to experts to get a comprehensive picture about the therapeutic effects of the drug, and learn new, the most recent data on its application. Colleagues shared their experience in the application of this drug, and discussed the possibilities of additional indications for its purpose and new perspectives for the use of this medication for the treatment of patients.

- What is the peculiarity of this symposium in terms of acquaintance of specialists with the product "Avodart"?

"The fact is that such a satellite symposium was held for the first time, and this, of course, the" pearl ": here we have the opportunity to systematically, thoroughly and scrupulously to determine the expediency of the use of this medicine in the treatment of patients with BPH. I want to say that now there are a lot of drugs for patients suffering from the disease, but only a small part of them has precisely pathogenetic effect, that is, suspend the further development of hyperplasia of the prostate and reduces the size of the prostate gland, acting directly on the cause of the disease. The majority of the other drugs have only symptomatic effect reduces the severity of symptoms of BPH. Of course, they also improve the condition of the patient, he reduces the severity of some of the symptoms of the disease, but it is important to remember that the disease itself these drugs do not cure. You can reduce the symptoms, but the prostate gland tumor will continue to grow. As a result, these patients may consult the doctors already too late - when medicamental pathogenetic therapy will not be able to help, and without surgical intervention will not do.

Therefore, one of the most important features of the prevention and treatment of this disease - timely treatment of the patient to the doctor and the selection of drug therapy, it is aimed at preventing the growth of the tumor and its reverse development. In this sense, the use of medications, such Avodart, it is difficult to overestimate.

- What prospects are opening up in front of the preparation "Avodart" in the light of the reports presented?

- Of course, the most wide-ranging. "Avodart" is still fairly new, but already now it is known that he has, in addition to the main therapeutic effect, there are still further, which will be the subject of further research. Therefore, the field of application of Avodart, obviously, will be expanded.

In addition, not all urologists and general practitioners are aware of this preparation: they do not yet have in its arsenal of experience of treatment of them. It is obvious, that in the future, as of receipt of the necessary information about Avodart, it will be applied more and more widely. With the help of "Avodart" we could open our patients new opportunities for recovery, for now, in addition to surgical treatment, the doctor will be able to provide more and conservative therapy BPH, with a comparable effect.

We not only help the patient deal with the cause of the disease, but, what is not less important, to help it to improve the quality of his life, and at the present time it is one of the leading indicators of the quality of the medical work. As a result of the course of treatment Avodart patients may simply be observed by a doctor twice a year passed inspection. And if the problem no longer occurs, you do not need any medication, or surgery. Of course, these possibilities for treatment - this is a real breakthrough in the treatment of this disease.

I think that this drug will take a worthy place among the leading drug in the treatment of BPH. The more doctors will receive the exhaustive information on the effectiveness of this drug, the more will apply it in therapy, the more colleagues will participate in scientific-practical conferences, similar to the previous symposium, in different regions of our country, the greater the number of our patients they will be able to help, without resorting to surgical treatment.

- What new information about the therapeutic possibilities of Avodart was announced at the symposium?

- It was announced a few important points about the indications to its application. Thus, there appeared new data concerning the duration of treatment with the drug "Avodart". To obtain the explicit and stable effect from the treatment of prostate adenoma need to pass a course of treatment lasting at least 12 months. In addition, the studies revealed the following feature: if the treatment Avodart started rather late, and surgical treatment of the patient was still necessary, on the background of therapy this drug is the percent of complications after operations significantly lower than those without such treatment.